Poland · Delayed Price · Currency is PLN Celon Pharma Statistics
Total Valuation
Celon Pharma has a market cap or net worth of PLN 1.07 billion. The enterprise value is 1.16 billion.
| Market Cap | 1.07B |
| Enterprise Value | 1.16B |
Important Dates
The last earnings date was Wednesday, September 16, 2026.
| Earnings Date | Sep 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Celon Pharma has 53.86 million shares outstanding. The number of shares has decreased by -2.77% in one year.
| Current Share Class | 38.86M |
| Shares Outstanding | 53.86M |
| Shares Change (YoY) | -2.77% |
| Shares Change (QoQ) | -10.58% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 17.98% |
| Float | 23.82M |
Valuation Ratios
The trailing PE ratio is 9.70.
| PE Ratio | 9.70 |
| Forward PE | n/a |
| PS Ratio | 4.14 |
| PB Ratio | 2.14 |
| P/TBV Ratio | 2.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 39.08 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 10.86 |
| EV / Sales | 4.50 |
| EV / EBITDA | 105.14 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.76, with a Debt / Equity ratio of 0.26.
| Current Ratio | 1.76 |
| Quick Ratio | 1.38 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | 3.94 |
| Debt / FCF | -2.27 |
| Interest Coverage | -1.55 |
Financial Efficiency
Return on equity (ROE) is 24.17% and return on invested capital (ROIC) is -0.63%.
| Return on Equity (ROE) | 24.17% |
| Return on Assets (ROA) | -0.50% |
| Return on Invested Capital (ROIC) | -0.63% |
| Return on Capital Employed (ROCE) | -0.74% |
| Weighted Average Cost of Capital (WACC) | 7.09% |
| Revenue Per Employee | 460,079 |
| Profits Per Employee | 190,734 |
| Employee Count | 564 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 2.33 |
Taxes
In the past 12 months, Celon Pharma has paid 36.81 million in taxes.
| Income Tax | 36.81M |
| Effective Tax Rate | 25.63% |
Stock Price Statistics
The stock price has decreased by -9.59% in the last 52 weeks. The beta is 0.63, so Celon Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | -9.59% |
| 50-Day Moving Average | 21.16 |
| 200-Day Moving Average | 21.00 |
| Relative Strength Index (RSI) | 35.49 |
| Average Volume (20 Days) | 17,130 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celon Pharma had revenue of PLN 257.64 million and earned 106.81 million in profits. Earnings per share was 2.04.
| Revenue | 257.64M |
| Gross Profit | 197.64M |
| Operating Income | -4.90M |
| Pretax Income | 143.62M |
| Net Income | 106.81M |
| EBITDA | 23.87M |
| EBIT | -4.90M |
| Earnings Per Share (EPS) | 2.04 |
Balance Sheet
The company has 34.54 million in cash and 128.44 million in debt, with a net cash position of -93.91 million or -1.74 per share.
| Cash & Cash Equivalents | 34.54M |
| Total Debt | 128.44M |
| Net Cash | -93.91M |
| Net Cash Per Share | -1.74 |
| Equity (Book Value) | 498.57M |
| Book Value Per Share | 9.26 |
| Working Capital | 54.04M |
Cash Flow
In the last 12 months, operating cash flow was 27.29 million and capital expenditures -83.92 million, giving a free cash flow of -56.63 million.
| Operating Cash Flow | 27.29M |
| Capital Expenditures | -83.92M |
| Depreciation & Amortization | 28.77M |
| Net Borrowing | 68.23M |
| Free Cash Flow | -56.63M |
| FCF Per Share | -1.05 |
Margins
Gross margin is 76.71%, with operating and profit margins of -1.90% and 41.46%.
| Gross Margin | 76.71% |
| Operating Margin | -1.90% |
| Pretax Margin | 55.74% |
| Profit Margin | 41.46% |
| EBITDA Margin | 9.27% |
| EBIT Margin | -1.90% |
| FCF Margin | n/a |
Dividends & Yields
Celon Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 2.77% |
| Shareholder Yield | 2.77% |
| Earnings Yield | 10.02% |
| FCF Yield | -5.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Celon Pharma is 20.44, which is 2.30% higher than the current price. The consensus rating is "Hold".
| Price Target | 20.44 |
| Price Target Difference | 2.30% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 9.39% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Celon Pharma has an Altman Z-Score of 3.49 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.49 |
| Piotroski F-Score | 4 |